Interfering Factors in Endotoxin Testing and an In-Depth Analysis of rFC Technology

Endotoxin testing is a critical component of quality control for biologics and pharmaceutical products; however, assay performance can be compromised by various interfering factors that may lead to inaccurate results and misinterpretation of product quality. Drawing on the authoritative guidance of USP <86> and PDA TR82, this article systematically examines the key sources of interference in endotoxin testing and their underlying mechanisms, with a particular focus on the distinct advantages of recombinant Factor C (rFC)-based technologies.

I. Interfering Factors and Mechanisms in Endotoxin Testing

(1) Interfering Components in Sample Matrices

• Chelating Agents and Surfactants

Chelating agents, such as citrate and EDTA, and surfactants, such as polysorbate 20 and polysorbate 80, are common sources of interference in endotoxin testing. Chelators disrupt the salt-bridge structure of endotoxin (LPS) by sequestering divalent cations, including Mg²⁺ and Ca²⁺. This process promotes the dissociation of LPS from aggregated forms into monomers, thereby reducing its effective interaction with detection reagents. Surfactants can further insert between LPS molecules to form mixed micelles, masking the biologically active sites of LPS and significantly impairing endotoxin recovery.

USP <86> reports that in antibody formulations containing 20 mM citrate and 0.02% polysorbate 20, the recovery observed with recombinant Factor C (rFC)-based assays was reduced to only 10–20%. In comparison, data cited in PDA TR82 indicate that endotoxin recovery using traditional LAL methods under the same conditions was even lower, falling below 5%.

• Proteins and Buffer Systems

High protein concentrations (>100 mg/mL) can interfere with endotoxin detection by binding LPS through hydrophobic interactions or electrostatic attraction, leading to the formation of biologically inactive complexes. For example, cationic proteins with an isoelectric point (pI) above 8.0 can strongly associate with negatively charged LPS, resulting in a 40–60% reduction in signal intensity in LAL-based assays.

Phosphate buffer systems, such as 25 mM Na₂HPO₄, may compete for divalent cations, thereby destabilizing LPS aggregates. Experimental data reported in PDA TR82 demonstrate that under these conditions, the apparent half-life of endotoxin can be reduced by more than 50%, directly compromising the accuracy and reliability of endotoxin test results.

(2) Impact of Detection Methods and Consumables

• Differences in Detection Principles Between LAL and rFC

LAL and rFC are the two primary approaches for endotoxin testing, but they differ markedly in specificity and resistance to analytical interference. LAL reagents contain Factor G, which is sensitive to β-glucans and may cause false-positive results. For example, the presence of 1 μg/mL β-glucan can lead to a two- to three-fold overestimation of endotoxin levels. In contrast, rFC assays specifically recognize the Lipid A moiety of LPS and show no cross-reactivity with β-glucans. In addition, LAL reagents are derived from horseshoe crab blood, and batch-to-batch variability may reach ±20%. rFC reagents, by comparison, are produced through recombinant expression, resulting in batch-to-batch variability of less than 5%. When combined with appropriate sample pretreatment strategies, rFC-based methods can also significantly improve endotoxin recovery, particularly in complex sample matrices.

Adsorption and Contamination from Consumables

The material composition and surface treatment of testing consumables can also introduce significant interference in endotoxin assays. Plastic labware, such as polypropylene, may adsorb LPS through hydrophobic interactions, resulting in a 10–30% reduction in measured endotoxin levels. Non-silanized glassware exhibits even higher adsorption capacity, with reported losses of up to 40%.

To minimize adsorption-related interference, PDA TR82 recommends the use of borosilicate glass tubes depyrogenated by dry heat at 250°C or validated, silanized plastic consumables specifically designed for endotoxin testing. These practices help ensure more accurate and reliable endotoxin recovery.

II. Technical Recommendations from USP and PDA

(1) Standardized Evaluation of Interference

According to USP <86>, laboratories are required to assess matrix interference through a suitability test. This is performed by analyzing spiked samples using rFC or rCR assays. If endotoxin recovery is below 50%, mitigation strategies may include sample dilution, supplementation with divalent cations such as Mg²⁺ (for example, 2 mM MgSO₄), or selection of an alternative testing method. PDA TR82 further recommends the use of a reverse hold-time study, in which samples are spiked at different time points and tested in parallel, in order to minimize the impact of batch-to-batch variability and better characterize time-dependent interference effects.

(2) Implementation Pathways for Method Transition

USP <86> permits the direct adoption of rFC-based methods for new drug applications without requiring formal comparability studies against LAL assays. For established products, however, a method change requires the submission of comparative data to demonstrate equivalent or improved performance. PDA TR82 emphasizes that when sample matrices contain high-risk interfering components, such as citrate or polysorbates, rFC may be preferentially selected as an alternative method to reduce the risk of LAL assay failure and avoid delays in product release.

III. Advantages of rFC–Based Endotoxin Testing

(1) Enhanced Resistance to Interference

Recombinant Factor C (rFC)–based endotoxin testing demonstrates markedly greater resistance to analytical interference compared with traditional LAL methods. rFC assays exhibit higher tolerance to chelating agents and surfactants commonly present in biopharmaceutical formulations. For example, in matrices containing 10 mM EDTA and 0.05% polysorbate 80, endotoxin recovery with rFC can be maintained at 85–95%, whereas recovery with LAL is typically limited to 30–50%. This improved robustness is largely attributable to the single-step reaction mechanism of rFC, which directly activates the initiating factor and avoids the multi-enzyme cascade in LAL assays that is more susceptible to inhibition by matrix components.

(2) Simplified Storage and Operation

rFC reagents are more convenient to store and handle. When stored at 2–8°C, rFC reagents generally maintain stability for up to 12 months, while LAL reagents often require storage at temperatures below –20°C and have comparable or shorter shelf lives. In addition, rFC assays do not require reagent preheating, reducing overall assay time by approximately 30% compared with LAL methods. The absence of β-glucan interference further simplifies operation, making rFC particularly suitable for samples with a higher risk of fungal contamination.

IV. Conclusion

Interference in endotoxin testing arises from sample matrix components, the properties of consumables, and inherent limitations of the detection method. Recombinant Factor C (rFC) technology, with its high specificity, stability, and resistance to interference, has been recognized by USP <86> as a supplemental method. PDA TR82 further demonstrates its practical applicability in complex matrices through case studies.

For reliable endotoxin testing, laboratories should integrate USP standards with PDA’s practical guidance, optimizing consumable selection, sample pretreatment, and methodological validation to ensure accurate and reproducible results.

Validation Data

• Validated across diverse sample matrices and buffer systems, the kit delivers robust anti-interference performance and consistently high endotoxin recovery.

Highly Recommended

• Eurofins Validated-Mycoplasma Rapid Detection Kit

• SAFENSURE™ Advanced Safety Testing Solution for Biologics

• resDetect™ Process Residue Detection Solutions

Endotoxin Testing Resource Series

Part 1: Strategies for Mitigating β-Glucan Interference in Endotoxin Detection

Part 2: Application of Recombinant Factor C Endotoxin Testing in Pharmaceutical Manufacturing

Part 3: Standards and Regulations for Recombinant Factor C Endotoxin Testing from a Pharmacopoeial Perspective

Part 4: Comparability Between Recombinant Factor C and Traditional LAL Assay in Endotoxin Detection

Part 5: A Comprehensive Guide to Sample Dilution Calculations for Recombinant Factor C Endotoxin Testing

Part 6: Key Considerations for Endotoxin Testing Experimental Procedures